Cefdinir Articles
Japan's NHI list gets 99 generics added
17 November 2008
Abbott Labs' 3rd-qtr 2007 net earnings flat
29 October 2007
Japan stock market week to Sept 17, 2007
24 September 2007
Teva sales forecast to reach $13.3B by 2010
16 July 2007
Teva gets generic Omnicef OK, starts shipping
21 May 2007
Abbott's 1st-qtr profit drops 19% to $697.5M
23 April 2007
Abbott suffers 4th-qtr $0.37 LPS on Kos buy
5 February 2007
Patent expiry will "constrain" antibacterial market
15 January 2007
Abbott's 2nd qtr profit drops on Guidant buy
24 July 2006
Final appro for Lupin's cefdinir capsules
5 June 2006
Abbott:13.4% 4th-qtr 2005 EPS growth, as expected
6 February 2006
Aspirations of Astellas Pharma, the merged Yamanouchi/Fujisawa
22 November 2004
Fujisawa fiscal 1st qtr 2005 sales dip 0.5%
16 August 2004
Abbott's 2nd-qtr 2004 sales rise 14%
19 July 2004
Abbott sees 13.9% rise in sales for 1st-qtr 2004
19 April 2004
Fujisawa reports 9-mth sales of 315B yen
23 February 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
Abbott's profits up 2%, forecasts lowered
27 January 2003
Xian-Janssen gets Cefzon rights
5 August 2002
Tokyo pharma stocks - week to July 15
22 July 2002
Glenmark pretax profits rise 54%
4 February 2002
Fujisawa sales soar in North America
12 November 2001
Medicis to license Abbott's Omnicef in USA
17 May 2001
Japan pharma stock market review - week to March 12
14 March 2001
Fujisawa gains ISO 14001 certificate for Takaoka plant
22 November 2000
Fujisawa fiscal 1999 turnover driven by Prograf
24 May 2000
Abbott acquire's US rights to Omnicef
9 December 1999
Fujisawa Reports Steady Interim Growth
11 November 1998
Omnicef Launched In The USA
6 October 1998
Warner-Lambert's Lipitor And Rezulin Will Fuel Growth
9 September 1998
Net Loss Plunges To $270 Million At Fujisawa
21 May 1998
W-L To Stay Independent As Product Line Improves
30 April 1998
W-L To Stay Independent As Product Line Improves
24 April 1998
Takeda, Diabetes Drive Japanese Blockbusters
19 February 1998
W-L's Omnicef Cleared For Marketing In USA
18 December 1997
Mixed Results From Japanese Drugmakers
12 November 1997
1st Half Decrease in Sales At Fujisawa
10 November 1997
Will New Wave Of Antibiotics Fight Resistance?
23 October 1997
Fujisawa Sees 31% Net Income Rise For FY1996
26 May 1997
Nonconsolidated Interims From Fujisawa
11 November 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
Japan's Fujisawa Looks To 21 Century Growth
16 October 1995
Warner-Lambert's cefdinir: new findings
2 October 1995
Fujisawa Net Down Though Operating Income Soars
29 May 1995
Atorvastatin Superior To Other Statins?
24 April 1995
Forecasts Revised At Fujisawa
10 October 1994
EXTRAORDINARY INCOME BOOSTS FUJISAWA IN 1994
30 May 1994
FUJISAWA NET INCOME DOWN 44.9% AT INTERIM
15 November 1993
PEDIATRIC CEFZON LAUNCHED IN JAPAN
14 June 1993
NET INCOME FALLS 77% IN 1992 AT FUJISAWA
31 May 1993
PROGRAF HEADS NEW JAPANESE APPROVALS
22 March 1993
JOUVEINAL PRODUCTS EFFECT ON W-L PIPELINE
8 February 1993
FUJISAWA'S PROMISING R&D PIPELINE
9 November 1992
FUJISAWA HIT BY JAPAN DRUG PRICING MOVES
1 June 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
FUJISAWA'S CEFZON LAUNCHED IN JAPAN
6 January 1992
Showing 1-68 of 68 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
